
Professor
Pediatrics
+1 415 476-5122
Kevin Shannon, MD studies signaling mechanisms that regulate the growth and differentiation of normal and leukemic stem cells. He is particularly interested in the genetic and biochemical basis of inherited leukemia predispositions and the regulation of hematopoietic stem cell and progenitor cell growth by Ras signaling.
Publications
5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
Leukemia
Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.
JCI insight
Precision Oncology for Papillary Craniopharyngioma.
The New England journal of medicine
The CCDI Comes Out of the Starting Block.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Sidestepping SHP2 inhibition.
The Journal of experimental medicine
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
Neuro-oncology
Chemical proteomic analysis of palmostatin beta-lactone analogs that affect N-Ras palmitoylation.
Bioorganic & medicinal chemistry letters
ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth.
Nature chemical biology
Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK.
Molecular cancer therapeutics
Soil and Seed: Coconspirators in Therapy-Induced Myeloid Neoplasms.
Blood cancer discovery
Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.
The Journal of clinical investigation
Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias.
PLoS genetics
High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.
Cell reports
Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.
Cold Spring Harbor perspectives in medicine
A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.
Cancer research
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Nature medicine
Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors.
Clinical cancer research : an official journal of the American Association for Cancer Research
Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.
Haematologica
KRAS insertion mutations are oncogenic and exhibit distinct functional properties.
Nature communications
CCR4 drives ATLL jail break.
The Journal of experimental medicine
PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
Science signaling
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
Clinical cancer research : an official journal of the American Association for Cancer Research
Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
Cancer discovery
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo.
Blood
Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis.
Science signaling
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
The Journal of clinical investigation
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Science translational medicine
Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.
Cancer research
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
Blood
Genetics, epigenetics, and leukemia.
The New England journal of medicine
Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia.
The Journal of experimental medicine
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.
Genes & development
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.
Proceedings of the National Academy of Sciences of the United States of America
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
American journal of medical genetics. Part A
Tumor suppressor gene inactivation in myeloid malignancies.
Best practice & research. Clinical haematology
Targeting Ras in myeloid leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.
Nature genetics
Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation.
Human mutation
Cancer: hay in a haystack.
Nature
Biochemical and functional characterization of germ line KRAS mutations.
Molecular and cellular biology
Targeting oncogenic Ras.
Genes & development
Hyperactive Ras in developmental disorders and cancer.
Nature reviews. Cancer
Deregulated Ras signaling in developmental disorders: new tricks for an old dog.
Current opinion in genetics & development
Sending out an SOS.
Nature genetics
Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders.
Cell cycle (Georgetown, Tex.)
Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.
Blood
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.
Pediatric blood & cancer
Harnessing preclinical mouse models to inform human clinical cancer trials.
The Journal of clinical investigation
Germline KRAS mutations cause Noonan syndrome.
Nature genetics
JAKing up hematopoietic proliferation.
Cancer cell
Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells.
The Journal of experimental medicine
RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Genes, chromosomes & cancer
The sum is greater than the FGFR1 partner.
Cancer cell
SHP-2 and myeloid malignancies.
Current opinion in hematology
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
Proceedings of the National Academy of Sciences of the United States of America
IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.
Proceedings of the National Academy of Sciences of the United States of America
Acute myeloid leukemia associated with t(8;21) or trisomy 8 in children with neurofibromatosis, type 1.
Journal of pediatric hematology/oncology
Mouse cancer models as a platform for performing preclinical therapeutic trials.
Current opinion in genetics & development
Acute leukemia: a pediatric perspective.
Cancer cell
Testing of new agents in childhood cancer preclinical models: meeting summary.
Clinical cancer research : an official journal of the American Association for Cancer Research
Ras processing as a therapeutic target in hematologic malignancies.
Current opinion in hematology
GTPase activating proteins: critical regulators of intracellular signaling.
Biochimica et biophysica acta